Posts

Showing posts with the label pitavastatin

moderate intensity statin plus ezetimibe in elderly

  A recent study found that moderate-intensity statins plus ezetimibe in the elderly was associated with similar LDL reduction to a high-intensity statin but decreased adverse effects (see   lipids elderly mod statin plus ezetimibe JIntMed2025  in dropbox, or doi: 10.1111/joim.20029)   Details : -- 561 patients who were at least 70yo with documented atherosclerotic cardiovascular disease (ASCVD) in South Korea were randomized to high-intensity statin therapy (rosuvastatin 20mg) vs moderate-intensity statin along with ezetimibe (rosuvastatin 5mg with ezetimibe 10mg) for 6 months in the SaveSAMS trial, a prospective, multicenter, open-label, randomized comparison at 11 sites -- mean age 77, 67% male, 62kg, BMI 24 -- hypertension in 74%, diabetes in 46%, chronic kidney disease in 21% (none of these were further defined: no info on actual BP, A1c, level of CKD) -- coronary artery disease in 92%, comprising  prior MI in 9%, percutaneous coron...

pitavastatin decreases pancreatic cancer and pancreatitis

  A recent article suggested  that the anti-inflammatory effects of pitavastatin may prevent pancreatic cancer by decreasing pancreatic inflammation (see statin dec pancreat cancer NatCommun2024  in dropbox, or doi.org/10.1038/s41467-024-48441-8)   Details:  -- see commentary below for more of the immunology and potential mechanisms   Results: -- mouse studies assessing chronic inflammation in the skin and pancreas: they created inflammation and fibrosis, documented that IL-33 expression was downstream of a specific signaling (TBK1-IRF-3), and that chronic inflammation depended on IL-33 induction -- they screened an FDA-approved drug library to assess the role of small molecules that would decrease IL-33 expression, finding 5 candidates. -- they found that pitavastatin calcium was an effective suppressant of IL-33 (as well as the bisphosphonate zoledronic acid)     -- pitavastatin suppressed a breast cancer cell line ...